Global Tocilizumab Market
市场规模(十亿美元)
CAGR : %
Forecast Period |
2024 –2031 |
Market Size (Base Year) |
USD 81.19 Million |
Market Size (Forecast Year) |
USD 203.93 Million |
CAGR |
|
Major Markets Players |
2023 年全球托珠单抗市场规模为 8119 万美元。市场份额预计将以 12.20% 的复合年增长率增长,到 2031 年达到 2.0393 亿美元。
托珠单抗是一种靶向白细胞介素 6 (IL-6) 受体的单克隆抗体。它可治疗各种疾病,包括类风湿性关节炎、幼年特发性关节炎和细胞因子释放综合征。托珠单抗通过抑制参与炎症过程的细胞因子 IL-6 起作用,从而减轻炎症和相关症状。托珠单抗的全球市场正在蓬勃发展,这得益于其适应症范围的扩大以及对炎症和自身免疫性疾病的精准治疗需求的增加。托珠单抗最初获准用于治疗类风湿性关节炎 (RA),其应用范围已扩大到包括幼年特发性关节炎(JIA)、巨细胞动脉炎 (GCA) 和与 CAR-T 细胞疗法相关的细胞因子释放综合征 (CRS)。
Data Bridge 市场研究市场报告提供了最新发展、市场份额、基于细分和区域分析的市场趋势、市场参与者的影响、新兴收入领域机会分析、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地理扩展、市场技术创新的详细信息。要获取有关市场的更多信息,请联系 Data Bridge 市场研究的专家分析师团队。我们的团队将帮助您做出明智的市场决策,以实现业务增长。
全球托珠单抗市场分析和市场规模
全球托珠单抗市场报告指标详情 |
|
|
报告指标 |
细节 |
|
预测期 |
2024-2031 |
|
基准年 |
2023 |
|
历史年份 |
2022(可定制 2016-2021) |
|
測量單元 |
百万美元 |
|
数据指针 |
市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景、深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。 |
Tocilizumab's ability to control intense inflammation and enhance patients' quality of life has significantly boosted its uptake. Moreover, its role in treating severe COVID-19 cases by addressing cytokine storms has expanded its market potential even further. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Phobic Disorders Treatment Market is increasing at a CAGR of 12.20%. Our detailed analysis forecasts that the market is valued at USD 81.19 Million in 2023 and is expected to grow up to USD 203.93 million by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.
Global Tocilizumab Market Dynamics
Global Tocilizumab Market Growth Drivers
Expanding Indications for Autoimmune Diseases
Tocilizumab's market growth is significantly driven by its expanding approval for various autoimmune conditions. For instance, its recent approval for systemic sclerosis has opened new avenues in regions such as North America and Europe, where systemic sclerosis is prevalent. Such broader application enhances Tocilizumab's market potential and underscores its role in addressing unmet needs in autoimmune disease management.
Increased Use in COVID-19 Treatment
Tocilizumab's market growth has been notably accelerated by its effective role in managing severe COVID-19 cases, particularly through its action against cytokine release syndrome (CRS). For instance, in the United States, the FDA granted Emergency Use Authorization (EUA) for Tocilizumab to treat COVID-19-associated CRS in hospitalized patients, leading to its widespread use in clinical settings.
Global Tocilizumab Market Growth Opportunities
Emergence in Biosimilars
The emergence of Tocilizumab biosimilars, such as the FDA-approved Trazimera by Amgen, exemplifies a transformative growth opportunity in the market. This biosimilar offers a cost-effective alternative to the original drug, enhancing accessibility and affordability for patients, especially in price-sensitive markets. As patents for Tocilizumab expire, biosimilars like Trazimera are poised to broaden the drug's reach, making it more accessible to a larger patient population and driving significant Global Tocilizumab Market growth.
Global Tocilizumab Market Growth Challenges
Different treatment alternatives
While tocilizumab has shown effectiveness in treating autoimmune disorders, patients and healthcare providers have access to various other treatment options. Alternative biologic disease-modifying antirheumatic drugs (DMARDs), such as adalimumab and etanercept, are also widely used for managing conditions like rheumatoid arthritis consequently, hampering the overall Global Tocilizumab Market growth.
托珠单抗成本高
托珠单抗的高成本对其可及性造成了重大障碍,尤其是在低收入和中等收入国家。该药的价格通常超过每治疗周期数千美元,对许多患者来说可能难以承受,从而限制了其广泛采用。与成本相关的挑战不仅限制了患者的可及性,而且还阻碍了这些经济受限地区的全球托珠单抗市场整体增长。
全球托珠单抗市场增长限制
限制市场扩张的法规
严格的审批流程和复杂的合规要求可能会延迟市场准入并限制托珠单抗在某些地区的供应。例如,在巴西,ANVISA 规定必须在该国进行试验,以评估该药物在巴西人群中的安全性和有效性。这项规定可能会大大延长药物审批时间并增加相关成本,给寻求引入新生物制剂的公司带来挑战,从而阻碍全球托珠单抗市场的增长。
全球托珠单抗市场范围和趋势
全球托珠单抗市场细分概述 |
|
市场 |
子段 |
产品类型 |
最低纯度小于 98%、最低纯度 98%-99%、最低纯度大于 99% |
应用 |
细胞因子释放综合征 (CRS)、系统性幼年特发性关节炎 (sJIA)、巨细胞动脉炎 (GCA)、类风湿性关节炎 (RA) |
分销渠道 |
医院药房、零售药房、网上药房 |
给药途径 |
口服、肠外、其他 |
人口统计 |
成人、儿童、老年 |
最终用户 |
诊所、医院、其他 |
剂量 |
注射剂、溶液、浓缩剂 |
- 对于之前对传统 DMARD 或生物制剂反应不足的活动性 RA 患者,TCZ-SC(皮下)单一疗法显示出与 TCZ-IV 相当的疗效和安全性。
- 将托珠单抗与其他药物(如托珠单抗-甲基泼尼松龙)联合使用,可以更有效地控制 CRS 并改善患者预后。
- 托珠单抗与逐渐减量治疗的糖皮质激素联合使用(或在糖皮质激素治疗后单独使用)可作为治疗复发或难治性疾病患者的巨细胞动脉炎的替代方法。这些患者尚未接受托珠单抗治疗。
全球托珠单抗市场区域分析 – 市场趋势
全球托珠单抗市场区域概览 |
|
|
地区 |
国家 |
|
欧洲 |
德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区 |
|
亚太地区 |
中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区其他地区 |
|
北美 |
美国、加拿大和墨西哥 |
|
中东及非洲 |
沙特阿拉伯、阿联酋、南非、埃及、以色列、中东其他地区和非洲 |
|
南美洲 |
巴西、阿根廷和南美洲其他地区 |
关键见解
- 北美占据市场主导地位,主要是因为其拥有先进的医疗基础设施、自身免疫性疾病的高患病率以及优惠的报销政策。尤其是美国是一个重要的市场,托珠单抗在获批适应症和说明书外用途中都有广泛使用,例如用于治疗严重的 COVID-19 病例
- 欧洲市场占有率高,这得益于人们对自身免疫性疾病的高度认识和强大的医疗保健系统。德国、法国和英国等国家是市场的主要贡献者,得益于生物疗法的广泛采用和政府支持慢性病管理的举措。
- 亚太地区正在成为一个快速增长的地区,医疗保健投资不断增加,自身免疫性疾病的发病率也不断上升。日本和中国引领着这一增长,日本成熟的制药业和中国不断扩张的生物仿制药市场在推动市场扩张方面发挥着关键作用。
- 巴西正逐渐成为拉丁美洲托珠单抗市场的重要参与者,这得益于其医疗保健行业的不断扩张和生物疗法的日益普及。该国的公共医疗保健系统 Sistema Único de Saúde (SUS) 正在努力将生物制剂整合到其治疗方案中,这可能会大大促进市场增长。
全球托珠单抗市场领先企业
- Bio-Rad Laboratories, Inc.(美国)
- SimSon Pharma Limited(印度)
- Selleck Chemicals(美国)
- Bio-Techne (美国)
- Biosynth (美国)
- BioVision Inc.(美国)
- CLEARSYNTH 实验室(美国)
- AbMole BioScience(美国)
- Biorbyt Ltd.(英国)
- 彭博金融有限责任公司 (美国)
- LifeSpan BioSciences, Inc(美国)
全球托珠单抗市场最新发展
- 2024年6月,Biogen Inc宣布欧盟委员会(EC)批准了基于ROACTEMRA的生物仿制药单克隆抗体TOFIDENCETM。欧盟委员会授予TOFIDENCE静脉制剂上市许可,用于治疗中度至重度活动性类风湿性关节炎、多关节型幼年特发性关节炎、全身型幼年特发性关节炎和COVID-19。
- 2024 年 3 月,FDA 批准了 Tyenne,这是第二个托珠单抗仿制药,也是第一个有静脉和皮下两种版本的仿制药。
- 2024年4月,Biogen宣布,罗氏公司RoActemra的生物仿制药Tofidence(tocilizumab-bavi)已被欧洲药品管理局人用药品委员会推荐用于治疗特定类型的关节炎和COVID-19。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.